JAK inhibition: the key to treating myeloproliferative neoplasm?
Expert Rev Hematol., Dec;5(6):583-5 (2012)
A surprising cause of masses in the chest.
Am. J. Hematol., Sep (2012)
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs.
J. Clin. Oncol., Nov;30(33):4098-103 (2012)
Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Mol Diagn Ther., Oct;16(5):269-83 (2012)
MPN blast phase: Clinical challenge and assessing response.
Leuk. Res., Dec;36(12):1496-7 (2012)
JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Expert Opin Investig Drugs., Dec;21(12):1755-74 (2012)
The evolving treatment paradigm in myelofibrosis.
Leuk. Lymphoma., Aug (2012)
Guideline for the diagnosis and management of myelofibrosis.
Br. J. Haematol., Aug;158(4):453-71 (2012)
Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Leuk. Res., Sep;36(9):1147-51 (2012)
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
J Hematol Oncol., 5:18 (2012)
JAK2 inhibitors and their impact in myeloproliferative neoplasms.
Hematology., Apr;17 Suppl 1:S129-32 (2012)
Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques.
Leuk. Res., Jun;36(6):664-71 (2012)
Clinical and laboratory features of myelofibrosis and limitations of current therapies.
Clin Adv Hematol Oncol., Sep;9(9 Suppl 22):1-16 (2011)
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
N. Engl. J. Med., Mar;366(9):799-807 (2012)
Nat Rev Drug Discov., Feb;11(2):103-4 (2012)
RNAi screening of the kinome with cytarabine in leukemias.
Blood., Mar;119(12):2863-72 (2012)
Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Curr Hematol Malig Rep., Mar;7(1):78-86 (2012)
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
Haematologica., Nov;96(11):1619-26 (2011)
Blood consult: resistant and progressive essential thrombocythemia.
Blood., Jul;118(2):240-2 (2011)
Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Leuk. Lymphoma., Jul;52(7):1178-87 (2011)
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
Blood., Jul;118(2):401-8 (2011)
Transplantation for myelofibrosis: time for a randomized trial.
Leuk. Res., Aug;35(8):987-8 (2011)
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
Cancer., Nov;117(21):4869-77 (2011)
The renaissance of interferon therapy for the treatment of myeloid malignancies.
Blood., May;117(18):4706-15 (2011)
Assessing new therapies and their overall impact in myelofibrosis.
Hematology Am Soc Hematol Educ Program., 2010:115-21 (2010)
International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
Am. J. Hematol., Jan;86(1):96-8 (2011)
Future therapies for the myeloproliferative neoplasms.
Curr Hematol Malig Rep., Mar;6(1):22-7 (2011)
A phase-2 trial of low-dose pomalidomide in myelofibrosis.
Leukemia., Feb;25(2):301-4 (2011)
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
N. Engl. J. Med., Sep;363(12):1117-27 (2010)
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.
Blood., Nov;116(22):4436-8 (2010)
Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.
IDrugs., Jun;13(6):394-403 (2010)
New drugs for the treatment of myelofibrosis.
Curr Hematol Malig Rep., Jan;5(1):15-21 (2010)
Detangling fibrosis assessment in MPNs.
Leuk. Res., Jul;34(7):854-5 (2010)
Phase1/-2 study of Pomalidomide in myelofibrosis.
Am. J. Hematol., Feb;85(2):129-30 (2010)
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
J. Clin. Oncol., Sep;27(27):4563-9 (2009)
Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
Expert Opin Emerg Drugs., Sep;14(3):471-9 (2009)
Itchy mast cells in MPNs.
Blood., Jun;113(23):5697-8 (2009)
Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.
Am. J. Hematol., May;84(5):265-7 (2009)
How I treat symptomatic splenomegaly in patients with myelofibrosis.
Blood., May;113(22):5394-400 (2009)
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.
Leuk. Res., Sep;33(9):1199-203 (2009)
Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
Eur. J. Haematol., Apr;82(4):255-9 (2009)
Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality.
Blood., Jan;113(5):1200-1 (2009)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Blood., Mar;113(13):2895-901 (2009)
BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis.
Mol. Cancer Ther., Aug;7(8):2339-47 (2008)
Risk factors for leukemic transformation in patients with primary myelofibrosis.
Cancer., Jun;112(12):2726-32 (2008)
New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.
Curr. Opin. Hematol., Mar;15(2):121-6 (2008)
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
Am. J. Hematol., May;83(5):363-5 (2008)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.
Leukemia., Apr;22(4):756-61 (2008)
Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.
Leuk. Res., May;32(5):691-8 (2008)
Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders.
Hematology Am Soc Hematol Educ Program., 355-62 (2007)
Am. J. Hematol., Feb;83(2):171 (2008)
A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Leukemia., Sep;21(9):1964-70 (2007)
Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.
Stem Cells., Sep;25(9):2358-62 (2007)
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Biologics., Jun;1(2):129-38 (2007)
Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.
Cancer., May;109(10):2083-8 (2007)
Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis.
Leuk. Res., Nov;31(11):1503-9 (2007)
The dawn of targeted therapy for primary myelofibrosis: opportunities and challenges.
Leuk. Res., Jul;31(7):883-6 (2007)
Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.
Curr Hematol Malig Rep., Feb;2(1):25-33 (2007)
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and
Leuk. Res., Jun;31(6):737-40 (2007)
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients.
Cancer., Jan;109(1):68-76 (2007)
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.
Br. J. Haematol., Dec;135(5):683-7 (2006)
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
Leukemia., Nov;20(11):2063-4 (2006)
Practical management of classical myeloproliferative disorder patients: a clinician's guide.
Future Oncol., Aug;2(4):515-24 (2006)
Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.
Leukemia., Oct;20(10):1800-8 (2006)
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Blood., Nov;108(10):3472-6 (2006)
Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
Best Pract Res Clin Haematol., 19(3):495-517 (2006)
Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.
Cancer., Jul;107(2):361-70 (2006)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
Blood., Sep;108(5):1497-503 (2006)
Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia.
Cancer., Jun;106(11):2406-11 (2006)
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Blood., Aug;108(4):1158-64 (2006)
Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
Cancer., May;106(9):1985-9 (2006)
JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.
Leuk. Res., Nov;30(11):1457-60 (2006)
Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy.
Cancer., Apr;106(8):1739-43 (2006)
A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.
Haematologica., Mar;91(3):415-6 (2006)
Tipifarnib: farnesyl transferase inhibition at a crossroads.
Expert Rev Anticancer Ther., Mar;6(3):313-9 (2006)
Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.
Cancer., Feb;106(3):623-30 (2006)
Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates.
Leuk. Res., Jun;30(6):677-80 (2006)
The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
Br. J. Haematol., Nov;131(3):320-8 (2005)
Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia.
Semin. Oncol., Aug;32(4):403-13 (2005)
PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.
Exp. Hematol., Jul;33(7):784-95 (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Cancer Cell., Apr;7(4):387-97 (2005)
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
Blood., Jul;106(1):318-27 (2005)
Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia.
Eur. J. Haematol., Feb;74(2):117-20 (2005)
Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
Eur. J. Haematol., Jan;74(1):47-53 (2005)
Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia.
Eur. J. Haematol., Jan;74(1):35-9 (2005)
Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients.
Br. J. Haematol., Jan;128(1):42-8 (2005)
Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.
Haematologica., Dec;89(12):1454-8 (2004)
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.
Blood., Feb;105(3):973-7 (2005)
Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.
Leuk. Lymphoma., Aug;45(8):1545-9 (2004)
Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment.
Intern. Med., Jul;43(7):540-7 (2004)
Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
Mayo Clin. Proc., Jul;79(7):883-9 (2004)
Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia.
Blood., May;103(9):3547-8 (2004)
Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
Br. J. Haematol., Oct;123(2):366-7 (2003)
Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment.
Mayo Clin. Proc., Oct;78(10):1223-33 (2003)